Novartis Is Dialing Out Of Its Listed Indian Arm – The Possibilities

Novartis initiates strategic review of listed Indian entity including taking a call on its 70.68% shareholding. Industry pundits point to potential suitors and options that may be at play.

Novartis reviews options for listed Indian arm • Source: Shutterstock

Way back in March 1996, Swiss pharmaceutical companies Ciba-Geigy and Sandoz. decided to merge and form what was then the world’s biggest life sciences combine christened Novartis.

More from Business

Boehringer Still Sees Plenty Of Juice In Jardiance

 
• By 

Strong sales growth for the German group’s SGLT2 inhibitor in 2024

Sumitomo Offloads Asia Pharma Ops To Marubeni For $480m

 
• By 

The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.

AIRNA To Take RNA Editing Into The Clinic With $155m Series B Round

 
• By 

CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.

Will They Or Won’t They? Tariff Question Looms For Drugmakers

 

Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.

More from Scrip

AIRNA To Take RNA Editing Into The Clinic With $155m Series B Round

 
• By 

CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.

Axsome Plans Excessive Sleepiness Study In Depression After Phase III Failure

 

The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.

Will They Or Won’t They? Tariff Question Looms For Drugmakers

 

Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.